


Blood Eosinophils and COPD


Despite advances in the management of COPD, tailoring therapy to individual patients is still a key challenge




This blood marker might help physicians decide on an individual patient basis who may/may not benefit from the addition of ICS to LAMA/LABA to reduce their risk of COPD exacerbations¹⁻⁵

Blood eosinophils may also assist in the decision of ICS discontinuation in selected patients^{3,4}

Blood eosinophils may help tailor therapy to individual patients with COPD



What is the right “cut-off-value”?



Reference: 1. Watz H, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. May 2016. 2. Bushnell N, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial. Am J Respir Crit Care Med. May 2017. 3. Harlander M, et al. Should Patients Switched from the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids? COPD: Int J Chron Obstruct Pulmon Dis. 2017. 4. Tariq S M, et al. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA? Int J Chron Obstruct Pulmon Dis. 2017. 5. Calverley P. Light in the Darkness? The FLAME Trial, Blood Eosinophils, and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. May 2017. 6. Medscape: Pulmonary Data Workup. Available at: <http://emedicine.medscape.com/article/301070-workup>. Last accessed: December 2017. 7. Calverley P, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. March 2017

